Results 41 to 50 of about 22,974 (229)

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

The frequency of agitation due to inappropriate use of naltrexone in addicts

Advanced Biomedical Research, 2014
Background: There is a high tendency among specialists to treat the addicts with naltrexone; withdrawal symptoms are frequent after taking naltrexone along with opioids.
Sima Siadat, Nastaran Eizadi-Mood, Ali Mohammad Sabzghabaee, Farzad Gheshlaghi, Ahmad Yaraghi   +4 more
doaj   +1 more source

Evaluating the optimal duration of medication treatment for opioid use disorder

Addiction, EarlyView.
Abstract Background and aims Clinicians have little guidance on the ideal length of time patients should remain on medication treatment for opioid use disorder (MOUD) before being able to safely discontinue MOUD. This study estimated how the risk of all‐cause mortality changes with the duration of MOUD, controlling for patient characteristics that ...
Corey J. Hayes, Rebecca A. Raciborski, Mahip Acharya, Nahiyan Bin Noor, Edward V. Nunes, T. John Winhusen   +5 more
wiley   +1 more source

Socio‐economic differences in the effectiveness of pharmacotherapy use in alcohol use disorder: A cohort study of 148 626 individuals in Sweden

Addiction, EarlyView.
Abstract Aim To examine the socioeconomic differences in the effectiveness of alcohol use disorders (AUD) pharmacotherapy and risk of AUD hospitalisation. Design A prospective register‐based cohort study. Setting Sweden. Participants Individuals who were registered as living in Sweden in 2005 (16–64 years) with a first‐time AUD diagnosis and complete ...
Devy L. Elling, Emelie Thern, Lluís Mangot‐Sala, Jari Tiihonen, Anders Hammarberg, Daniel Falkstedt, Heidi Taipale   +6 more
wiley   +1 more source

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol‐free and low‐alcohol products in higher risk groups

Addiction, EarlyView.
Abstract Alcohol‐free and low‐alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high‐income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol‐related health problems should take a zero‐tolerance approach to these alcohol‐like products or encourage patients to ...
John Holmes, Christopher K. Oldroyd, Colin Drummond, Matt Field, Inge Kersbergen, Michael E. D. Allison   +5 more
wiley   +1 more source

Drug use among people in prison: A global review of epidemiology, harms and interventions

Addiction, EarlyView.
Abstract Background and aims People who use drugs are overrepresented in the criminal justice system. We aimed to provide a broad synthesis of the epidemiology, harms and interventions related to drug use and drug use disorders among incarcerated adults worldwide, and highlight gaps in evidence and practice.
Louis Favril, John Strang, Seena Fazel
wiley   +1 more source

Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide

Harm Reduction Journal, 2012
Background Respiratory depression, a potentially fatal side-effect of opioid-overdose, may be reversed by timely administration of an opioid antagonist, such as naloxone or naltrexone.
Goli Veeraindar, Webster Lynn R, Lamson Michael J, Cleveland Jody M, Sommerville Kenneth W, Carter Eric   +5 more
doaj   +1 more source

Secondary analysis of a combined harm‐reduction treatment and extended‐release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth

Addiction, EarlyView.
Abstract Background and Aims In a prior randomized clinical trial (RCT), combined pharmacobehavioral harm‐reduction treatment improved alcohol outcomes and physical health‐related quality of life (PH‐QoL). In this secondary analysis, we tested race, ethnicity and sex assigned at birth as predictors and moderators of these effects.
Silvi C. Goldstein, Nicole H. Weiss, Manshu Yang, Sarah W. Feldstein Ewing, Susan E. Collins   +4 more
wiley   +1 more source

Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography

BMC Research Notes, 2012
Background Naltrexone has been proven to be an effective treatment option for the treatment of alcohol dependency. In this article we introduce a reliable and simple method developed for the simultaneous determination of naltrexone and 6-β-naltrexol in ...
Heinälä Pekka, Lahti Tuuli, Sinclair David, Ariniemi Kari, Lillsunde Pirjo, Alho Hannu   +5 more
doaj   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source